2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Gene Editing, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Gene Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

2592 Beyond freedom from crises: the “new normal” and post-treatment needs after sickle cell gene therapy

Rakhshanda Ramzan, MHS, BSN, RN, Belinda Mandrell2, Akshay Sharma Jr, MBBS3, Yvonne Carroll, RN, JD4, Abagail Cohen, MA, HEC-C5, Jami Gattuso, MSN, RN, CPON, FAPHON6, Ambria Williams7, Raven Simpson, BSN, RN8, Mary Caples, MA, CCRP9, Yoram Unguru, MD, MS, MA, HEC-C10, Liza Johnson, MD, MPH, MSB, HEC-C11
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 Herman and Walter Samuelson Children's Hospital at Sinai, Baltimore, Maryland, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Introduction: Clinical reports of sickle cell disease (SCD) gene therapy (GT) appropriately emphasize reduced vaso-occlusive events, hematologic response, and safety. These endpoints do not capture how patients and caregivers experience life after treatment, including residual morbidity, psychosocial adaptation, and transition from intensive SCD care to long-term post-GT follow-up. We characterized patient- and caregiver-defined outcomes and support needs after SCD GT. 

Methods: GENETX is an IRB-approved prospective mixed-methods needs assessment. The study conducted semi-structured interviews with 15 participants (10 patients, 5 caregivers) who had undergone SCD GT at centers across the United States. Interviews examined treatment experiences, satisfaction and regret, information participants wished they had received, life after treatment, and post-treatment support needs. Recordings were transcribed verbatim and analyzed in MAXQDA using semantic content analysis with deductive and inductive coding. This analysis focused on perceived benefit, residual morbidity, treatment burden, psychosocial adaptation, care continuity and support, and retrospective decision appraisal. 

Results: Profound benefit and unfinished recovery coexisted in accounts of GT. Participants described fewer pain crises and hospitalizations, a return to age-appropriate activities, and a “new life”; 13 of 14 (92%) responding to the regret question reported no regret about GT. Despite positive appraisals, participants described persistent pain and established SCD morbidity, including organ injury and cardiac and cognitive complications, plus effects of prolonged hospitalization and conditioning. Preparation gaps included post-discharge monitoring, changes in treatment teams, infertility or menopausal effects, and the distinction between preventing future SCD events and reversing pre-existing morbidity. Participants described a “new normal” marked by fear, loneliness, survivor guilt, identity change, caregiver burden, and need for mental health support. They also described discontinuity between GT/transplant and hematology teams and difficulty returning to school or work. Of 14 participants responding about resources/supports, 7 reported no unmet needs; coded gaps among the remainder included discharge preparation, team continuity, mental-health services, peer support, or school support. This variation demonstrates that post-GT needs were substantial for some but not uniform. 

Conclusions: For patients and families, successful GT is not an endpoint but a transition to a new phase of care. Counseling should distinguish prevention of future SCD events from reversal of established organ damage and prepare families for treatment-related late effects, residual morbidity, and an uncertain “new normal.” A survivorship framework incorporating explicit team handoffs, longitudinal symptom assessment, mental-health resources, and school/work reintegration should complement hematologic endpoints and align therapeutic success with outcomes patients and families value. 

Liza Johnson, MD, MPH, MSB, HEC-C: ECRI Horizon Scanning - Honoraria; CSL Behring - Honoraria